Anti-Infective Restrictions at Nebraska Medicine

Restricted anti-infective approval process:

- 1. All orders for restricted anti-infectives must be reviewed and approved by an infectious diseases (ID) service (or other service as outlined below). The ordering physician is responsible for contacting an approving service.
- 2. If an order is received by pharmacy and it is not clear that use criteria are met or approval has been gained, the pharmacist will enter the order to remain active for 24 hours (exception, CMV-IG see table below) and contact the ordering team to request they obtain approval. Because the order will be stopped in 24 hours, the review and approval must be initiated within 24 hours of the original order.
- 3. If use is approved, ID will relay this information to the ordering physician as well as to the pharmacy. If the restricted anti-infective is thought to be inappropriate, ID will provide alternative recommendations and communicate these recommendations to the physician originating the order.
- 4. ID may decide that a formal consultation is necessary for approval. In this instance, a formal ID consultation will be required for use of the restricted agent.

Drug	Approving services	Indications not requiring approval	Notes
Ceftolozane/tazobactam (Zerbaxa)	ID	None	
Colistin (IV and inhaled)	ID, pulmonary	None	Requires formal consultation by ID or pulmonary service
CMV-IG (Cytogam)	Transplant ID	If ordered via P&T- approved order set (visceral transplant)	First dose is not dispensed without approval
Daptomycin (Cubicin)	ID	FDA-approved indications (skin/skin structure infections, <i>S. aureus</i> bacteremia)	
Fosfomycin (Monurol)	No approval required	Single-dose fosfomycin for simple cystitis can be used without restriction	Documented susceptibility required if requiring more than one dose
Peramivir (Rabivab)	ID	None	
Posaconazole (Noxafil)	ID, heme/onc	None	
Ribavirin for HSV	ID, heme/onc	Continuation of home therapy for hepatitis C	Oral ribavirin only
Tigecycyline (Tygacil)	ID	None	

ID: infectious diseases service, CMV-IG: cytomegalovirus immune globulin

For further details and updated restrictions refer to the Antimicrobial Stewardship Program website at: www.nebraskamed.com/ASP